Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Second University of Naples |
---|---|
Information provided by: | Second University of Naples |
ClinicalTrials.gov Identifier: | NCT00478543 |
The purpose of this study is to verify the efficacy of diuretic therapy on blood pressure control and left ventricular mass in patients affected by chronic kidney disease
Condition | Intervention | Phase |
---|---|---|
Chronic Kidney Disease |
Drug: Furosemide |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Effect of Loop Diuretics Treatment on Blood Pressure Control in Phase 3-4 of Chronic Kidney Disease |
Enrollment: | 40 |
Study Start Date: | September 2005 |
Study Completion Date: | July 2008 |
Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Diuretic: Experimental
Furosemide
|
Drug: Furosemide |
In CKD, impairment of renal function causes fluid and sodium retention and consequently expansion of extracellular volume, which corresponds to about 5% of body weight in absence of peripheral edema. In particular, sodium retention increases exponentially as glomerular filtration rate declines and is of primary importance in the pathogenesis of hypertension. Therefore, reduction of salt intake in renal patients allows a better blood pressure control.
Despite the evidence collected on the beneficial effects of salt restriction in CKD, compliance with dietary prescription is generally poor in patients followed up in the real world of clinical practice. In the presence of poor adherence to salt restriction, diuretics agents become the cornerstone of treatment of hypertension secondary to CKD. Disappointingly, nephrologists are reluctant to "adequately" use loop diuretics in their hypertensive CKD patients, probably because of the fear of side effects and of the amazing absence in medical literature of studies of middle-long term on diuretic efficacy. Therefore, the primary aim of this study is to evaluate efficacy and safety of loop diuretics on blood pressure control in patients affected by CKD.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Italy | |
Nephrology Department, Second University of Naples | |
Naples, Italy, 80138 |
Study Chair: | Giuseppe Conte, Professor | Second University of Naples |
Responsible Party: | Chair of Nephrology Second University of Naples ( Giuseppe Conte ) |
Study ID Numbers: | LD1-22052007 |
Study First Received: | May 24, 2007 |
Last Updated: | February 3, 2009 |
ClinicalTrials.gov Identifier: | NCT00478543 History of Changes |
Health Authority: | Italy: Ethics Committee |
Loop diuretics Chronic Kidney Disease Hypertension Blood pressure control Left ventricular mass |
Renal Insufficiency Urologic Diseases Renal Insufficiency, Chronic Diuretics Kidney Failure, Chronic Cardiovascular Agents |
Kidney Diseases Sodium Potassium Chloride Symporter Inhibitors Furosemide Kidney Failure Hypertension |
Renal Insufficiency Molecular Mechanisms of Pharmacological Action Diuretics Physiological Effects of Drugs Kidney Failure, Chronic Cardiovascular Agents Furosemide Pharmacologic Actions |
Membrane Transport Modulators Urologic Diseases Renal Insufficiency, Chronic Natriuretic Agents Therapeutic Uses Kidney Diseases Sodium Potassium Chloride Symporter Inhibitors Kidney Failure |